Are Dietary Bioactives Ready for Recommended Intakes?12 by Gaine, P. Courtney et al.
 
Are Dietary Bioactives Ready for Recommended Intakes?12
 
 
(Article begins on next page)
The Harvard community has made this article openly
available.
Please share how this access benefits you. Your story
matters.
Citation Gaine, P. Courtney, Douglas A. Balentine, John W. Erdman,
Johanna T. Dwyer, Kathleen C. Ellwood, Frank B. Hu, and
Robert M. Russell. 2013. “Are Dietary Bioactives Ready for
Recommended Intakes?12.” Advances in Nutrition 4 (5): 539-
541. doi:10.3945/an.113.004226.
http://dx.doi.org/10.3945/an.113.004226.
Published Version doi:10.3945/an.113.004226
Accessed February 16, 2015 10:15:57 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987256
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and
conditions applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAASN 2013 ANNUAL MEETING SYMPOSIUM SUMMARY
Are Dietary Bioactives Ready
for Recommended Intakes?
1,2
P. Courtney Gaine,
3* Douglas A. Balentine,
4 John W. Erdman Jr.,
5 Johanna T. Dwyer,
6 Kathleen C. Ellwood,
7 Frank B. Hu,
8
and Robert M. Russell
9
3North American Branch of the International Life Sciences Institute, Washington, DC;
4Unilever, Englewood Cliffs, NJ;
5University of Illinois, Urbana,
IL;
6Tufts University Medical School, Boston, MA;
7College of Southern Maryland, La Plata, MD;
8Harvard School of Public Health, Cambridge, MA;
9Tufts University, Boston, MA; and National Institute of Health, Bethesda, MD
ABSTRACT
Research has shown that numerous dietary bioactive components that are not considered essential may still be beneﬁcial to health. The dietary
reference intake (DRI) process has been applied to nonessential nutrients, such as ﬁber, yet the majority of bioactive components await a
recommended intake. Despite a plethora of new research over the past several years on the health effects of bioactives, it is possible that the ﬁeld
may never reach a point where the current DRI framework is suitable for these food components. If bioactives are to move toward dietary
guidance, they will likely require an alternative path to get there. Adv. Nutr. 4: 539–541, 2013.
Introduction
For more than 70 y, U.S. consumers have relied upon the
RDAs and the dietary reference intakes (DRIs) for intake re-
commendations of essential nutrients. These reference values
describe the relationships among nutrient intakes and indi-
cators of adequacy, prevention of chronicdisease, and avoid-
ance of excessive nutrient intakes in healthy populations.
Although a framework exists to establish recommendations
for essential nutrients, such a framework does not exist for
nonessential bioactive constituents in foods. Bioactives in-
clude those food components such as ﬁber, carotenoids, ﬂa-
vonoids, and n-3 long-chain fatty acids that may be oxidized
as fuels, may provide compounds for endogenous synthesis
of body constituents, cannot be synthesized by the body, and
do not result in biochemical or clinical deﬁciency. Evidence
is emerging that, although not essential to life, these compo-
nents confer a range of effects that may support health and
quality of life. However, because they have physiological
roles not considered essential to humans and because a myr-
iad offactors makemeasuringtheir intakesand studying their
effects difﬁcult, an alternative framework to determine rec-
ommended intakes for bioactives is warranted. The pur-
pose of this symposium was to address the fundamental
question: What will it take to develop a framework that
can be used for establishing health recommendations for bi-
oactive food components? While the session primarily fo-
cused on ﬂavonoids, many of the points raised pertained
to bioactives in general.
Dr. Kathy Ellwood provided an overview of the evidence
needed to set dietary recommendations, laying out elements
for consideration in adapting the current DRI framework for
application to bioactives. Dr. Frank Hu provided an over-
view of the state of the science on ﬂavonoid intake and health
beneﬁts and identiﬁed challenges and future needs to further-
ing our understanding of ﬂavonoids and health. Dr. Johanna
Dwyer reviewed case studies using ﬂavonoid subclasses, ad-
dressing their safety, health beneﬁts, and evaluated whether
the current evidence was sufﬁciently strong to meet the sci-
entiﬁc rigor for intake recommendations. Dr. John Erdman
provided a historical perspective on the evaluation of bio-
actives by identifying the progress made during the past 20 y.
The symposium concluded with a panel discussion led
by Dr. Robert M. Russell, whose experience as chair of
the Institute of Medicine’s Food and Nutrition Board and
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sion on future actions needed if bioactives are to be consid-
ered for intake recommendations.
Current Framework for Developing Dietary
Recommendations
Several elements are required for a nutrient or food compo-
nent to be evaluated for a dietary recommendation. First,the
data must demonstrate consistent results indicating that the
effects of the food component of interest can be attributed
to a health impact, including a plausible mechanism of ac-
tion. Second, accurate intake assessment is needed, with bio-
markers of exposure and/or validated food assessment methods
required, including the ability to distinguish the effects of
the background diet. Large, randomized, controlled inter-
vention studies and studies of humans are typically given
the greatest weight in the evaluation. However, because chro-
nic disease develops over a long period of time, making in-
tervention studies sometimes prohibitive, biomarkers of effect
or risk biomarkers from observational data are also depended
upon. A biomarker is a reliable and accurate indicator of
normal biological processes, pathogenic processes, or phar-
macologic responses to an intervention. Surrogate endpoints
of chronic disease are risk biomarkers that serve as a substi-
tute for clinical endpoints, but few are validated and not all
risk biomarkers are surrogate endpoints.
An important public health question is whether intake
recommendations should shift focus from disease risk re-
duction to maintenance of normal physiological function
(e.g., enhanced blood ﬂow). Moving beyond classic nutri-
ent-disease biomarkers may be essential in the development
of dietary recommendations for bioactives. Although main-
taining or improving physiological functions may support
optimal health, the challenge is that markers of enhanced
physiological function do not always reside in a causal path-
way for disease risk reduction, making them ineligible as
valid biomarkers. There are many emerging biological indi-
cators of disease risk/health that may be potential interme-
diary biomarkers and these are likely critical to the ability
to attribute ﬂavonoid intake to beneﬁcial health outcomes.
For this shift to be possible, more studies validating these mark-
ers’ ability to predict health outcomes are needed. Addition-
ally, multiple risk biomarkers may be helpful if all show the
same beneficial effect on a particular health outcome.
State of the Science and the Complex Reality of
Research on Flavonoids
There are 6 subclasses of ﬂavonoids in the diet, deﬁned by
structure. Flavonoid intake has been linked to reduced risk
for chronic diseases as well as to improved health outcomes,
such as appropriate platelet aggregation and ﬂow-mediated di-
lation. The potential mechanisms for the biological function of
ﬂavonoids vary by structure and include activities such as bind-
ing at hormone receptor sites, activating endogenous defense
systems, modulating cell signaling pathways, having antiinﬂam-
matory effects, and inhibiting intestinal glucose transporters.
In recent years, there has been a surge in research on
the bioactivity and health beneﬁts of bioactive food com-
ponents, including ﬂavonoids. Substantial observational
evidence exists for beneﬁcial effects of the intake of ﬂavo-
noids and ﬂavonoid-rich food and beverages such as choco-
late, fruits, tea, and vegetables on decreasing risk of chronic
diseases. Small, short-term trials have found potential ben-
eﬁts of ﬂavan-3-ols, in particular, on blood pressure, endo-
thelial function, and insulin resistance and of green tea on
blood lipids. However, larger and longer term trials are
needed to validate the ﬁndings. Future research is needed
to clarify whether the observed beneﬁcial outcomes result
from ﬂavonoids or from other dietary constituents. Speciﬁ-
cally, large, prospective cohort studies in combination with
shorter term trials of intermediary endpoints are critical in
establishing causality in the absence of trials with disease
endpoints.
Is the Current Science Enough for Dietary
Recommendations?
In 1998, phenols, polyphenols, and ﬂavonoids were excluded
from the DRI panel’s consideration due to lack of food com-
position data and knowledge of actual intake amounts and
limited information on their absorption and metabolism.
The DRI committee report concluded that although these
components “may be important dietary constituents, insuf-
ficient data are available. at this time.” The report also
stated that with regard to “food components grouped as
‘other food components,’.. other data may emerge in the
future that could allow a consideration of setting DRIs for
these compounds as well.” The amount of evidence needed
is at hand for discussion, including consideration of the risk:
benefit ratio of consuming the constituent. For example, a
high-risk, low-benefit constituent should require more evi-
dence (e.g., selenium and cancer prevention given selenium
excess may be toxic) and one with low risk and high benefit
may require less (e.g., potentially lutein and age-related
macular degeneration, for which there is little evidence of
harm). One of the larger obstacles in such an evaluation is
the lack of randomized clinical trials of intakes and health
outcomes. However, it is difficult to run trials with bioac-
tives due to the costs of a large study population of long du-
ration to detect small effects. In addition, even if studies are
successful, they may not provide sufficient data for convinc-
ing systematic, evidence-based reviews. Another issue is the
complexity that results from grouping data from all sub-
classes of flavonoids, constituting total flavonoids, and as-
suming that one body of evidence should and will have a
single effect. In reality, flavonoids differ in the quantities
found in foods, bioavailability, metabolites they produce,
and the health effects they may have.
Does the Science, the Framework, or Both
Need Fixing?
Developing a path forward for dietary recommendations for
bioactive components will require evidence-based scientiﬁc
data. There is consensus within the scientiﬁc community that
540 Symposiumit must strive to generate literature that is valid and reliable
so that consistent results are demonstrated. During the past
several decades, in addition to the increased number of stud-
ies, there have been improvements in the design, intake as-
sessment, substance characterization, biomarker discovery,
and reporting of research on ﬂavonoids and other bioactives.
Although these enhancements to the science must and will
continue, the possibility exists that the ﬁeld of bioactives
can never provide the same type of evidence that essential
nutrients do, and thus the question is whether they should
be considered under the same framework as the DRI. If they
should not, a concerted effort requiring expert resources and
funding will be required to develop an alternative path to
recommended intakes for bioactives. One logical next step
is for the Institute of Medicine’s Food and Nutrition Board
to develop and test a blueprint that can be used to evaluate
each of these constituents in a formal review of the type that
is required for establishing a DRI.
Consequences of Inaction
From a public health perspective, without dietary recom-
mendations for ﬂavonoids and other bioactives, there is a
perpetuation of the status quo of current dietary patterns
containing lower intakes of bioactive-containing foods than
may support optimal health. Consumer confusion is also
of concern and yet, at the same time, leaves an “open range”
of intake amounts suggested for dietary supplement claims.
Conveying accurate and reliable information about the health
benefits of many of these bioactive food components would
enhance the public’s understanding of the importance of
safe use of these compounds for promoting optimal health.
For the scientificcommunity, dietary recommendations stimu-
late research, and without momentum forward, there may
be a dearth of the type of critical research needed to close
the gaps in knowledge.
In Summary
Some of the challenges and obstacles that bioactives face with
regard to making intake recommendations are given below.
These are followed by future actions likely needed for clear-
ing the path forward to dietary intake recommendations for
ﬂavonoids and other bioactive compounds.
Challenges/Obstacles to Intake Recommendations ·
The bioavailability and bioactivity of flavonoid subclasses differ
widely according to chemical structure. ·
Flavonoid intake from dietary supplements and foods differs
in content, matrices, and dose consumed. ·
The polyphenol contentof plantfoods is influenced bynumer-
ous factors (i.e., sun, ripeness, storage, preparation, processing,
etc.), making accurate assessment of flavonoid intake difficult. ·
There are errors in intake measurement (i.e., accuracy of food
composition databases, reliabilityof FFQs, and intakeamounts
do not always equate to bioavailable doses). ·
The health benefits of flavonoids in the current literature are
often based on surrogate biomarkers of effect rather than ac-
tual health outcomes (endpoints), such as disease incidence
or mortality. ·
Given that bioactives are nonessential, the funding required in
undertaking a formal federal review of their intake has not been
viewed as a priority.
Future Actions Needed ·
Continue to increase the focus on hypothesis-driven research
rather than “fishing expeditions.” ·
Strengthen the science and craft messages that reflect that the
benefits of flavonoids justify intake recommendations. ·
Shift the focus of conducting and evaluating research toward
biomarkers of function and health and wellness compared
with disease risk reduction. ·
Continue to explore and validate biomarkers of intake and
metabolites and incorporate these in dietary assessment of
large prospective studies. ·
Replicate studies on various subpopulations of interest. ·
Continue efforts to harmonize the characterization of bioac-
tive components in research. ·
Fund and conduct larger and longer term trials, using accepted
and new biomarkers of effect. ·
Use advanced statistical techniques (e.g., mixed evidence syn-
thesis, cross design synthesis, including the confidence profile
method) to better summarize existing data. ·
Demonstrate the safety of bioactives for intended uses for sup-
plements and conventional foods. ·
Further explore the independent and synergistic effects of
multiple compounds to delineate the bioactivities and health
effects of specific flavonoids. ·
Solidify funding to make the evaluation of bioactives possible.
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